

Date of last issue: 13.09.2019

## **Ganirelix Formulation**

Revision Date:

SDS Number:

Version

| .3     | 16.10.2020                                | 22215-00016                     | Date of first issue: 15.10.2014   |
|--------|---|---------------------------------|---|
| ECTION | 1. PRODUCT AND CO                         | MPANY IDENTIFIC                 | ATION   |
| Produ  | ct name                                   | : Ganirelix Form                | ulation   |
|        | facturer or supplier's                    | details                         |   |
|        | any name of supplier                      | : Organon & Co                  |   |
| Addre  |   |                                 | e Septiembre No. 301  |
|        |   | Xaltocan - Xoc                  | himilco Mexico 16090  |
| Telepł |   | : 52 55 5728444                 | 14  |
|        | gency telephone<br>I address              | : 215-631-6999<br>: EHSSTEWAR   | D@organon.com   |
| Recor  | nmended use of the c                      | hemical and restri              | ctions on use   |
| Recon  | nmended use                               | : Pharmaceutica                 | al  |
| ECTION | 2. HAZARDS IDENTIFI                       |                                 |   |
|        | Classification                            |                                 |   |
| Repro  | ductive toxicity                          | : Category 1B                   |   |
|        | ic target organ toxicity<br>ated exposure | : Category 1 (Bo                | one marrow, Liver, Adrenal gland, spleen, Ovar  |
| GHS I  | abel elements                             |                                 |   |
| Hazar  | d pictograms                              |                                 |   |
| Signal | Word                                      | : Danger                        |   |
| Hazar  | d Statements                              | : H360Fd May c<br>unborn child. | lamage fertility. Suspected of damaging the   |
|        |   | H372 Causes                     | damage to organs (Bone marrow, Liver, Adrena<br>Ovary) through prolonged or repeated exposure |
| Preca  | utionary Statements                       | Prevention:                     |   |
|        |   | P201 Obtain s                   | pecial instructions before use.   |
|        |   |                                 | andle until all safety precautions have been rea  |
|        |   | and understoo                   |   |
|        |   |                                 | reathe mist or vapors.  |
|        |   |                                 | in thoroughly after handling.<br>at, drink or smoke when using this product.                  |
|        |   |                                 | otective gloves/ protective clothing/ eye protective  |
|        |   | Response:                       |   |
|        |   |                                 | F exposed or concerned: Get medical advice/   |
|        |   | attention.                      |   |
|        |   | attention.<br>Storage:          |   |



## **Ganirelix Formulation**

| ersion<br>3 | Revision Date:<br>16.10.2020                        | SDS Number:<br>22215-00016  |   | sue: 13.09.2019<br>sue: 15.10.2014                 |  |
|-------------|---|---|---|--|--|
|             |   | <b>Disposal:</b><br>P501 Dispo<br>posal plant.                      | se of contents/ contai  | iner to an approved waste dis-                     |  |
| •           | r <b>hazards</b><br>known.                          |   |   |  |  |
| ECTION      | 3. COMPOSITION/INF                                  | ORMATION ON I   | NGREDIENTS  |  |  |
| Subst       | tance / Mixture                                     | : Mixture   |   |  |  |
| Comp        | ponents   |   |   |  |  |
| Chem        | nical name  |   | CAS-No.   | Concentration (% w/w)                              |  |
| Ganir       | elix  |   | 124904-93-4   | >= 0.01 -< 0.1                                     |  |
|             |   | advice.   |   |  |  |
| lf inha     | aled  |   | emove to fresh air.   |  |  |
|             |   | Get medical   | attention.  |  |  |
|             | se of skin contact                                  | of water.<br>Remove cor<br>Get medical<br>Wash clothi<br>Thoroughly | ntaminated clothing a<br>attention.<br>ng before reuse.<br>clean shoes before re  | euse.  |  |
| In cas      | se of eye contact                                   |   | with water as a preca<br>attention if irritation of   | ution.<br>develops and persists.                   |  |
| lf swa      | allowed   | Get medical   | <ul> <li>If swallowed, DO NOT induce vomiting.</li> <li>Get medical attention.</li> <li>Rinse mouth thoroughly with water.</li> </ul>   |  |  |
|             | important symptoms<br>iffects, both acute and<br>ed | : May damag<br>child.   | e fertility. Suspected  | of damaging the unborn<br>gh prolonged or repeated |  |
|             | ction of first-aiders                               | : First Aid res<br>and use the<br>when the po                       | First Aid responders should pay attention to self-protection,<br>and use the recommended personal protective equipment<br>when the potential for exposure exists (see section 8). |  |  |
| NI. (       | s to physician                                      | <ul> <li>Treat sympt</li> </ul>                                     | omatically and suppo  | ortively   |  |

#### SECTION 5. FIRE-FIGHTING MEASURES

| Suitable extinguishing media   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO2)<br>Dry chemical |
|--------------------------------|---|---|
| Unsuitable extinguishing media | : | None known.   |
| Specific hazards during fire   | : | Exposure to combustion products may be a hazard to health.                    |



## **Ganirelix Formulation**

| Versi<br>6.3 | ion   | Revision Date:<br>16.10.2020 |    | 0S Number:<br>215-00016   | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014   |  |
|--------------|---|------------------------------|----|---|---|--|
| I            | fighting<br>Hazard<br>ucts  |                              | :  | No hazardous cor  | nbustion products are known   |  |
|              | Specific extinguishing meth-<br>ods   |                              | :  | Use extinguishing measures that are appropriate to local cir-<br>cumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do<br>so.<br>Evacuate area. |   |  |
|              | Special protective equipment for fire-fighters                                |                              | :  | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |   |  |
| SEC          | TION 6  | . ACCIDENTAL RELE            | AS | E MEASURES  |   |  |
| t            | Personal precautions, protec-<br>tive equipment and emer-<br>gency procedures |                              | :  |   | ective equipment.<br>ing advice (see section 7) and personal<br>ent recommendations (see section 8).                                    |  |
|              | Environmental precautions   |                              | :  | Prevent spreading<br>oil barriers).<br>Retain and dispos  | he environment.<br>akage or spillage if safe to do so.<br>g over a wide area (e.g., by containment or<br>se of contaminated wash water. |  |

Local authorities should be advised if significant spillages cannot be contained.

| Methods and materials for containment and cleaning up | : | Soak up with inert absorbent material.<br>For large spills, provide diking or other appropriate<br>containment to keep material from spreading. If diked material<br>can be pumped, store recovered material in appropriate<br>container.<br>Clean up remaining materials from spill with suitable<br>absorbent.<br>Local or national regulations may apply to releases and<br>disposal of this material, as well as those materials and items |
|---|---|--|
|   |   | employed in the cleanup of releases. You will need to<br>determine which regulations are applicable.<br>Sections 13 and 15 of this SDS provide information regarding<br>certain local or national requirements.  |

### SECTION 7. HANDLING AND STORAGE

| Technical measures      | See Engineering measures ur<br>CONTROLS/PERSONAL PRO  |   |
|-------------------------|---|---|
| Local/Total ventilation | If sufficient ventilation is unava<br>ventilation.  | ilable, use with local exhaust              |
| Advice on safe handling | Do not get on skin or clothing.<br>Do not breathe mist or vapors<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after ha<br>Handle in accordance with goo<br>practice, based on the results | ndling.<br>od industrial hygiene and safety |



## **Ganirelix Formulation**

| Version<br>6.3 | Revision Date:<br>16.10.2020 | SDS Number:<br>22215-00016   | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014  |  |  |  |
|----------------|------------------------------|--|--|--|--|--|
|                |                              | assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to th<br>environment. |  |  |  |  |
| Hygie          | ne measures                  | flushing syste<br>place.<br>When using d<br>Wash contam<br>The effective<br>engineering c<br>appropriate de<br>industrial hygi   | chemical is likely during typical use, provide eye<br>ms and safety showers close to the working<br>lo not eat, drink or smoke.<br>inated clothing before re-use.<br>operation of a facility should include review of<br>ontrols, proper personal protective equipment,<br>egowning and decontamination procedures,<br>iene monitoring, medical surveillance and the<br>strative controls. |  |  |  |
| Condi          | itions for safe storage      | Store locked u<br>Keep tightly c   |  |  |  |  |
| Mater          | ials to avoid                |  | with the following product types:<br>ng agents   |  |  |  |

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components | CAS-No.     | Value type<br>(Form of<br>exposure) | Control parame-<br>ters / Permissible<br>concentration | Basis    |
|------------|-------------|-------------------------------------|--|----------|
| Ganirelix  | 124904-93-4 | TWA                                 | 0.2 μg/m3 (OEB<br>5)                                   | Internal |
|            |             | Wipe limit                          | 2 µg/100 cm <sup>2</sup>                               | Internal |

| Engineering measures :        | Use closed processing systems or containment technologies<br>to control at source (e.g., glove boxes/isolators) and to<br>prevent leakage of compounds into the workplace.<br>All engineering controls should be implemented by facility<br>design and operated in accordance with GMP principles to<br>protect products, workers, and the environment.<br>No open handling permitted.<br>Totally enclosed processes and materials transport systems<br>are required.<br>Operations require the use of appropriate containment<br>technology designed to prevent leakage of compounds into<br>the workplace. |
|-------------------------------|--|
| Personal protective equipment |  |
| Respiratory protection :      | No personal respiratory protective equipment normally required.  |
| Hand protection               | -  |

## **Ganirelix Formulation**



| Version<br>6.3            | Revision Date: 16.10.2020 | SDS Number:<br>22215-00016   | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014   |  |
|---------------------------|---------------------------|--|---|--|
| Material                  |                           | : Chemical-res   | istant gloves   |  |
| Remarks<br>Eye protection |                           | If the work er<br>mists or aero<br>Wear a faces                                    | ble gloving.<br>glasses with side shields or goggles.<br>wironment or activity involves dusty conditions,<br>sols, wear the appropriate goggles.<br>hield or other full face protection if there is a<br>lirect contact to the face with dusts, mists, or   |  |
| Skin and body protection  |                           | : Work uniform<br>Additional bo<br>task being pe<br>disposable su<br>Use appropria | <ul> <li>Work uniform or laboratory coat.</li> <li>Additional body garments should be used based upon the<br/>task being performed (e.g., sleevelets, apron, gauntlets,<br/>disposable suits) to avoid exposed skin surfaces.</li> <li>Use appropriate degowning techniques to remove potentially<br/>contaminated clothing.</li> </ul> |  |

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

| Appearance  | : | Aqueous solution    |
|---|---|---------------------|
| Color   | : | No data available   |
| Odor  | : | No data available   |
| Odor Threshold                                      | : | No data available   |
| рН  | : | 5                   |
| Melting point/freezing point                        | : | No data available   |
| Initial boiling point and boiling range             | : | 100 °C              |
| Flash point   | : | No data available   |
| Evaporation rate                                    | : | No data available   |
| Flammability (solid, gas)                           | : | Not applicable      |
| Flammability (liquids)                              | : | No data available   |
| Upper explosion limit / Upper<br>flammability limit | : | No data available   |
| Lower explosion limit / Lower<br>flammability limit | : | No data available   |
| Vapor pressure                                      | : | 23 hPa (20 °C)      |
| Relative vapor density                              | : | No data available   |
| Relative density                                    | : | 1                   |
| Solubility(ies)<br>Water solubility                 | : | completely miscible |



## **Ganirelix Formulation**

| Version<br>6.3 | Revision Date:<br>16.10.2020  |             | S Number:<br>215-00016                                      | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014 |
|----------------|---|-------------|---|---|
| octa<br>Auto   | tion coefficient: n-<br>nol/water<br>ignition temperature<br>omposition temperature | :<br>:<br>: | No data available<br>No data available<br>No data available | 2   |
|                | osity<br>iscosity, kinematic<br>osive properties                                    | :           | No data available<br>Not explosive                          | 9   |
| Mole           | izing properties<br>cular weight<br>cle size  | :<br>:<br>: | The substance o<br>No data available<br>No data available   | -   |

#### SECTION 10. STABILITY AND REACTIVITY

| Reactivity<br>Chemical stability<br>Possibility of hazardous reac-<br>tions | : | Not classified as a reactivity hazard.<br>Stable under normal conditions.<br>Can react with strong oxidizing agents. |
|---|---|--|
| Conditions to avoid   | : | None known.  |
| Incompatible materials  | : | Oxidizing agents   |
| Hazardous decomposition<br>products   | : | No hazardous decomposition products are known.   |

#### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

#### Acute toxicity

Not classified based on available information.

#### **Components:**

# **Ganirelix:** Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

#### Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.





| rsion<br>B   | Revision Date: 16.10.2020   | SDS Number:<br>22215-00016  | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014   |
|--|---|---|---|
| <u>Com</u>   | oonents:  |   |   |
| Ganir  | elix:   |   |   |
| Speci  |   | : Rabbit  |   |
| Resul  |   | : Mild eye irritatio  | n   |
| Metho  | od  | : Draize Test   |   |
| Respi  | ratory or skin sens   | itization   |   |
| -  | sensitization<br>assified based on av   | ailable information.  |   |
|  | ratory sensitizatior  |   |   |
|  | assified based on av  |   |   |
| Comp   | oonents:  |   |   |
| Ganir  | elix:   |   |   |
| Test 7   |   | : Maximization Te   | est   |
|  |   |   |   |
| Speci  | 53  | : Guinea pig  |   |
| Speci<br>Resul   |   | : negative  |   |
| Resul<br>Germ<br>Not cl                                  |   | : negative  |   |
| Resul<br>Germ<br>Not cl                                  | t<br><b>cell mutagenicity</b><br>assified based on av<br>ponents:                               | : negative  |   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br><b>cell mutagenicity</b><br>assified based on av<br>ponents:                               | : negative<br>ailable information.<br>: Test Type: reve   | rse mutation assay  |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | : negative<br>ailable information.<br>: Test Type: reve<br>Test system: Sa  | almonella typhimurium   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | : negative<br>ailable information.<br>: Test Type: reve   | almonella typhimurium   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | : negative<br>ailable information.<br>: Test Type: reve<br>Test system: Sa<br>Result: negative  | almonella typhimurium   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | : negative<br>ailable information.<br>: Test Type: reve<br>Test system: Sa<br>Result: negative<br>Test Type: reve<br>Test system: Es  | almonella typhimurium<br>s<br>rse mutation assay<br>scherichia coli   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | : negative<br>ailable information.<br>: Test Type: reve<br>Test system: Sa<br>Result: negative<br>Test Type: reve   | almonella typhimurium<br>s<br>rse mutation assay<br>scherichia coli   |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative<br/>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> </ul>   | almonella typhimurium<br>rse mutation assay<br>scherichia coli  |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative<br/>Test Type: reve<br/>Test system: Es<br/>Result: negative<br/>Test system: Es<br/>Result: negative</li> </ul>  | almonella typhimurium<br>rse mutation assay<br>scherichia coli  |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir          | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative<br/>Test Type: reve<br/>Test system: Es<br/>Result: negative<br/>Test system: Es<br/>Result: negative</li> </ul>  | almonella typhimurium<br>e<br>rse mutation assay<br>scherichia coli<br>e<br>tro test<br>hinese hamster ovary cells                                  |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir<br>Genot | t<br>cell mutagenicity<br>assified based on av<br>ponents:<br>elix:                             | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative</li> <li>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> <li>Test Type: in vit<br/>Test system: Ch<br/>Result: negative</li> </ul>  | almonella typhimurium<br>e<br>rse mutation assay<br>scherichia coli<br>e<br>tro test<br>ninese hamster ovary cells                                  |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir<br>Genot | t<br>cell mutagenicity<br>assified based on av<br><u>ponents:</u><br>elix:<br>coxicity in vitro | <ul> <li>inegative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative</li> <li>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> <li>Test Type: in vit<br/>Test system: Ch<br/>Result: negative</li> <li>Test Type: In vit<br/>Species: Mouse</li> </ul>   | almonella typhimurium<br>rse mutation assay<br>scherichia coli<br>tro test<br>ninese hamster ovary cells<br>vo micronucleus test                    |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir<br>Genot | t<br>cell mutagenicity<br>assified based on av<br><u>ponents:</u><br>elix:<br>coxicity in vitro | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative</li> <li>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> <li>Test Type: in vit<br/>Test system: Ch<br/>Result: negative</li> <li>Test Type: In vit<br/>Species: Mouse<br/>Application Rou</li> </ul>                      | almonella typhimurium<br>rse mutation assay<br>scherichia coli<br>tro test<br>hinese hamster ovary cells<br>vo micronucleus test<br>te: Intravenous |
| Resul<br>Germ<br>Not cl<br><u>Comp</u><br>Ganir<br>Genot | t<br>cell mutagenicity<br>assified based on av<br><u>ponents:</u><br>elix:<br>coxicity in vitro | <ul> <li>inegative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative</li> <li>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> <li>Test Type: in vit<br/>Test system: Ch<br/>Result: negative</li> <li>Test Type: In vit<br/>Species: Mouse</li> </ul>   | almonella typhimurium<br>rse mutation assay<br>scherichia coli<br>tro test<br>hinese hamster ovary cells<br>vo micronucleus test<br>te: Intravenous |
| Resul<br>Germ<br>Not cl<br>Comp<br>Ganir<br>Genot        | t<br>cell mutagenicity<br>assified based on av<br><u>ponents:</u><br>elix:<br>coxicity in vitro | <ul> <li>negative</li> <li>ailable information.</li> <li>Test Type: reve<br/>Test system: Sa<br/>Result: negative</li> <li>Test Type: reve<br/>Test system: Es<br/>Result: negative</li> <li>Test Type: in vit<br/>Test system: Ch<br/>Result: negative</li> <li>Test Type: In vit<br/>Species: Mouse<br/>Application Rou<br/>Result: negative</li> </ul> | almonella typhimurium<br>rse mutation assay<br>scherichia coli<br>tro test<br>hinese hamster ovary cells<br>vo micronucleus test<br>te: Intravenous |

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

## **Ganirelix Formulation**



| Version<br>6.3 | Revision Date:<br>16.10.2020       |   | S Number:<br>215-00016  | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014   |
|----------------|------------------------------------|---|---|---|
| <u>Co</u>      | mponents:                          |   |   |   |
| Gai            | nirelix:                           |   |   |   |
| Effe           | ects on fertility                  | : | Species: Rat<br>Application Route<br>Duration of Single<br>Fertility: LOAEL:<br>Result: Effects or<br>Test Type: Fertilit<br>Species: Rat, fen<br>Application Route | e Treatment: 13 Weeks<br>0.1 µg/kg<br>n fertility.<br>ty/early embryonic development<br>nale<br>e: Subcutaneous<br>e Treatment: 8 Weeks                         |
|                |                                    |   | Result: No effects<br>Test Type: Fertili<br>Species: Monkey<br>Application Route  | s on mating performance., Effects on fertility.<br>ty<br>e: Subcutaneous<br>0.02 mg/kg body weight  |
| Effe           | ects on fetal development          | : | Species: Rat, fen<br>Application Route<br>Embryo-fetal toxi<br>Result: Embryo-fetal<br>Test Type: Embry<br>Species: Rabbit,<br>Application Route                    | e: Subcutaneous<br>city.: LOAEL: 10 μg/kg<br>etal toxicity.<br>yo-fetal development<br>female<br>e: Subcutaneous  |
|                | productive toxicity - As-<br>sment | : | Result: Embryo-f<br>Clear evidence o<br>fertility, based on   | city.: LOAEL: 30 μg/kg<br>etal toxicity.<br>f adverse effects on sexual function and<br>animal experiments., Some evidence of<br>n development, based on animal |

#### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

#### Components:

#### Ganirelix:

| Routes of exposure | : | Ingestion   |
|--------------------|---|---|
| Target Organs      | : | Bone marrow, Liver, Adrenal gland, spleen, Ovary      |
| Assessment         | : | Causes damage to organs through prolonged or repeated |
|                    |   | exposure.   |





| ersion<br>3 | Revision Date: 16.10.2020       | SDS Number:<br>22215-00016  | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014 |
|-------------|---------------------------------|---|---|
| Repe        | ated dose toxicity              |   |   |
| Com         | oonents:                        |   |   |
| Ganir       | relix:                          |   |   |
| Expos       | ΞL                              | : Rat<br>: 0.02 mg/kg<br>: 2 mg/kg<br>: Subcutaneous<br>: 6 Months<br>: Bone marrow |   |
| Expos       |                                 | : Mouse, female<br>: 0.3 mg/kg<br>: Subcutaneous<br>: 3 Months<br>: Liver, Adrenal  | gland, spleen, Ovary  |
| Expos       |                                 | : Mouse, male<br>: 3 mg/kg<br>: Subcutaneous<br>: 3 Months<br>: Liver, Adrenal      | gland, spleen   |
|             | EL<br>cation Route<br>sure time | : Monkey<br>: 2.5 mg/kg<br>: Subcutaneous<br>: 6 Months<br>: No significant a       | adverse effects were reported                                     |

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Ganirelix:

Inhalation

: Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

### **SECTION 12. ECOLOGICAL INFORMATION**

Ecotoxicity

**Components:** 

Ganirelix:

#### Ecotoxicology Assessment

| Acute aquatic toxicity | : | No data available |
|------------------------|---|-------------------|
|------------------------|---|-------------------|

| Chronic aquatic toxicity | : No data available |
|--------------------------|---------------------|
|--------------------------|---------------------|



## **Ganirelix Formulation**

| 3   | Revision Date:<br>16.10.2020  | SDS Number:<br>22215-00016   | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014   |
|---|---|--|---|
|   | stence and degradab   | ility  |   |
|   | ata available   |  |   |
|   | ccumulative potential<br>ata available  |  |   |
|   | <b>lity in soil</b><br>ata available  |  |   |
|   | r adverse effects<br>ata available  |  |   |
| ECTION  | 13. DISPOSAL CONS   | IDERATIONS   |   |
|   | osal methods  |  |   |
|   | e from residues<br>aminated packaging   | : Empty conta<br>handling site   | accordance with local regulations.<br>iners should be taken to an approved waste<br>for recycling or disposal.<br>se specified: Dispose of as unused product. |
| ECTION  | 14. TRANSPORT INF   | ORMATION   |   |
| Intor   | national Regulations  |  |   |
|   | -   |  |   |
| UNR<br>Not re   | egulated as a dangerou  | s good   |   |
|   | -DGR<br>egulated as a dangerou  | s good   |   |
| INOT LE   |   |  |   |
| IMDG  | <b>i-Code</b><br>egulated as a dangerou   | s good   |   |
| IMDG<br>Not re<br>Trans   | egulated as a dangerou<br>sport in bulk accordin  | g to Annex II of M   | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Trans<br>Not a  | egulated as a dangerou  | g to Annex II of M   | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Trans<br>Not a<br>Dome  | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as  | g to Annex II of M<br>s supplied.  | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Not a<br>Dome<br>NOM<br>Not re<br>Spec  | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT  | <b>g to Annex II of M</b><br>s supplied.<br>s good   | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Not a<br>Dome<br>NOM<br>Not re<br>Spec<br>Not a   | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT<br>egulated as a dangerou<br>ial precautions for us<br>pplicable   | g to Annex II of M<br>s supplied.<br>Is good<br>er   | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Not a<br>Dome<br>NOM<br>Not re<br>Spec<br>Not a   | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT<br>egulated as a dangerou<br>ial precautions for us  | g to Annex II of M<br>s supplied.<br>Is good<br>er   | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Not a<br>Dome<br>NOM<br>Not re<br>Spec<br>Not a   | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT<br>egulated as a dangerou<br>ial precautions for us<br>pplicable<br>15. REGULATORY IN<br>y, health and environ   | g to Annex II of M<br>s supplied.<br>Is good<br>er<br>FORMATION  | ARPOL 73/78 and the IBC Code  |
| IMDG<br>Not re<br>Trans<br>Not a<br>Dome<br>NOM<br>Not re<br>Spec<br>Not a<br>ECTION<br>Safet<br>mixtu<br>Feder<br>esser  | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT<br>egulated as a dangerou<br>ial precautions for us<br>pplicable<br>15. REGULATORY IN<br>y, health and environ   | g to Annex II of M<br>s supplied.<br>s good<br>er<br>FORMATION<br>mental regulations<br>of chemical precurs<br>and machinery for               | s/legislation specific for the substance or   |
| IMDG<br>Not re<br>Trans<br>Not a<br>Dome<br>Not a<br>Spec<br>Not a<br>ECTION<br>Safet<br>mixtu<br>Fedel<br>esser<br>produ | egulated as a dangerou<br>sport in bulk accordin<br>pplicable for product as<br>estic regulation<br>-002-SCT<br>egulated as a dangerou<br>ial precautions for us<br>pplicable<br>15. REGULATORY IN<br>y, health and environ<br>ure<br>ral Law for the control c | g to Annex II of M<br>s supplied.<br>s good<br>er<br>FORMATION<br>mental regulations<br>of chemical precurs<br>and machinery for<br>and pills. | s/legislation specific for the substance or   |



## **Ganirelix Formulation**

| Version<br>6.3 | Revision Date:<br>16.10.2020 | SDS Number:<br>22215-00016 | Date of last issue: 13.09.2019<br>Date of first issue: 15.10.2014 |  |
|----------------|------------------------------|----------------------------|---|--|
| DSL            |                              | : not determined           |   |  |
| IECS           | C                            | : not determined           |   |  |

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

| Sources of key data used to compile the Material Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/ |
|--|---|--|
|--|---|--|

Revision Date : 16.10.2020

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8